Physician profile
Tina L Skinner
NPI 1235585712
$911.74
in general payments reported to CMS, 2019-2025
10 companies · $492 in 2025
The $492 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $258 · 2024: $162 · 2025: $492.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $912.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $911.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $266.45 | 2023-2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $156.94 | 2023-2024 | Caplyta |
| Braeburn INC. | $123.07 | 2025 | Brixadi |
| Tris Pharma INC | $120.13 | 2023 | Quillivant, Dyanavel Xr, Quillichew Er |
| E.R. Squibb & Sons, L.L.C. | $119.31 | 2025 | Cobenfy |
| Lundbeck LLC | $49.83 | 2023-2024 | Rexulti, Abilify Maintena |
| Janssen Pharmaceuticals, INC | $32.05 | 2023 | Spravato |
| Almatica Pharma LLC | $16.52 | 2023 | Loreev Xr |
| Neurocrine Biosciences, INC. | $13.82 | 2023 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $13.62 | 2024 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tina Skinner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.